Investor Center

NASDAQ: ABVC

Vital Statistics

$0.9884 ( -3.0775225% )

SHARE PRICE

398,356

SHARES TRADED

10,560,400

TOTAL SHARES

$10,437,899.00

MARKET CAP

$1.07  HIGH

$0.9411  LOW

$0.0316 PRICE CHANGE

$1.02  PREVIOUS CLOSE

$1.06 OPENING PRICE

$1.02  CLOSING PRICE

$9.60  52-WEEK HIGH

$0.674  52-WEEK LOW

NEW: Summer 2023 Investor Presentation

View the latest product information, status updates, financial information, and more.

Last Updated: 6 mins ago
SAFE HARBOR STATEMENT

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Investor Considerations

  • Strong portfolio of medicines and medical devices addresses wide range of disorders.
  • In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.
  • MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.
  • Botanical expertise leads to medicines with fewer side effects.
  • Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.
  • Business model designed to minimize burn rate.
  • Less than 30 million shares outstanding.

Attention Shareholders


BACKGROUND

Leadership Team

NASDAQ: ABVC

Latest News

THERAPEUTIC FOCUS

Retinal Vitrectomy

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM